Microport Scientific Corp. · HKEX:853
Microport Scientific — H1 2025 Earnings Presentation
26 slides from Microport Scientific's earnings presentation, September 2025
Slide 1: MicroPort Scientific Corporation 2025 Interim Results
MicroPort Scientific Corporation 2025 Interim Results September 2025 1 |
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of,
Slide 3: Contents
Contents Company Highlights Business Review Financial Review Appendix
Slide 4: 1H25 Financial Results
1H25 Financial Results 18.1% 9.6% $ 20.8% 5.3% Cardiovascular 2.0% Orthopedics 5.5% CRM Endovascular Neurovascular 16.1% Heart valve 22.6% Surgical robots Others $ 7.7% 50.6% 29.0% The PRC North America Europe Asia (excluding the PRC) 8.7% South America 2.7% Others 1.3% Note: 1. revenue growth rate
Slide 5: 1H25 Portfolio Highlights
1H25 Portfolio Highlights $128M ~$60M Going-abroad EBITDA 116%YOY Revenue 57.3%YOY Cardiovascular Net profit 64.4%YOY Increasing sales contribution of active device Net loss narrowed 58%YOY FDA approval for domestic total Orthopedics EBITDA 28.5%YOY knee system CRM EBITDA breakeven Not Applicabl
Slide 6: Positioning for Next Chapter of Value Creation
Positioning for Next Chapter of Value Creation Welcoming a new strategic shareholder. Complementing product portfolio with diversified products and product pipelines as a cardiology platform. Facilitate the development of MicroPort®’s core businesses by leveraging SIIC Capital’s state-owned en
Slide 7: We Are Proud to Receive Another World-class Recognition
We Are Proud to Receive Another World-class Recognition Premium Quality Firehawk® Rapamycin Target Eluting Coronary Stent System Cost-effectiveness Accessibility 1-Month DAPT with Firehawk® Stents Lowers Advances patient outcomes and generates clear health- Bleeding without Increasing Ischemic E
Slide 8: Our Unique Infrastructure
Our Unique Infrastructure 1H25 Going-abroad Updates 1H25 Innovation Updates ~$ 60mn 57.3% 4 20 232 Sales Revenue YOY Growth NMPA Green Paths NMPA Approvals Overseas Approvals (Class III initial) GloMatrix Platform Domestic TomaHawk® Integrated Coronary Intravascular Lithotripsy System Firelimus® Co
Slide 9: Contents
Contents Company Highlights Business Review Financial Review Appendix
Slide 10: Cardiovascular Business: Net Profit Increased by 64.4%
Cardiovascular Business: Net Profit Increased by 64.4% Revenue Net Profit China USD: million USD: million Maintaining leading position while actively integrating product portfolio Non-China (2.1)% • 1H25 revenue remained stable, among which the DES products maintained No.1 China 64.4% market shar
Slide 11: Orthopedics Business: Net Loss Narrowed by 58% with Positive FCF
Orthopedics Business: Net Loss Narrowed by 58% with Positive FCF China Revenue • 1H25 revenue (2.8)%YOY, due to delayed execution of 2nd round VBP and lags in the transition between old and new growth USD: million drivers due to short-term product mix adjustments. • Seizing the transition window of
Slide 12: CRM Business: EBITDA Breakeven
CRM Business: EBITDA Breakeven China Revenue • 1H25 revenue (1.0)%YOY due to delayed VBP execution. USD: million • Revenue contribution from ICD products came in 1H25 for the first time. • Continuous efforts in developing hospital penetration of our substantially enriched product pipeline incl. impo
Slide 13: Endovascular Business
Endovascular Business Product Pre-clinical Clinical Registration Revenue Overseas Revenue Net Profit L-REBOA® Aortic Occlusion Balloon USD: million USD: million USD: million Catheter • NMPA approved 9 17 56 17 43 Obtained NMPA approval Aortic Intervention 9 Cratos® Branched Aortic Stent-Graft Non-
Slide 14: Neurovascular Business
Neurovascular Business Product Pre-clinical Clinical Registration Revenue Overseas Revenue Net Profit Tubridge® Flow-diverting Stent for small USD: million USD: million USD: million Obtained NMPA approval and medium-sized aneurysm Hemorrhagic Stroke Non-China 7 Numen® Silk 3D Electronically 4 7 4
Slide 15: Structural Heart Diseases Business: Net Loss Narrowed 96%
Structural Heart Diseases Business: Net Loss Narrowed 96% Product Pre-clinical Clinical Registration Revenue Overseas Revenue Net Loss VitaFlow® • NMPA approved USD: million USD: million USD: million • Registered in Argentina and Thailand 2.7% 1H24 1H25 Non-China 1 4 4 VitaFlow Liberty® • NMPA appr
Slide 16: Surgical Robot Business: Net Loss Narrowed 59% with FCF Improved 43%
Surgical Robot Business: Net Loss Narrowed 59% with FCF Improved 43% Product Pre-clinical Clinical Registration Revenue Overseas Revenue Net Loss USD: million USD: million USD: million Toumai® Laparoscopic • NMPA approved 77% 1H24 1H25 Surgical Robot • 30+ registration approvals globally 14 Non-Chi
Slide 17: Contents
Contents Company Highlights Business Review Financial Review Appendix
Slide 18: Income Statement Highlights
Income Statement Highlights Revenue Gross Margin USD: million -2.2% -280 bps 558.7 547.5 59.2% 56.4% 1H24 1H25 1H24 1H25 Operating Expenses Operating Expenses Ratio% USD: million -14.5% -810 bps 355.0 63.5% 303.5 55.4% 83.8 15.0% 82.8 15.1% Administrative Administrative 156.2 Expenses Expenses 27.9%
Slide 19: Income Statement Highlights (Continued)
Income Statement Highlights (Continued) Net Loss Non-HKFRS Adjusted Net Loss EBITDA USD: million USD: million USD: million Breakeven 10.0 1H24 1H25 1.2 - 116% 1H24 1H25 127.8 (10.0) (20.0) （36.4） (30.0) (40.0) (50.0) 59.1 (60.0) (64.1) (70.0) 66% (106.7) narrowed 1H24 1H25 2025 Interim Results Finan
Slide 20: Cashflow Highlights
Cashflow Highlights Operating Cashflow Capital Expenditure Adjusted Cash and Cash Equivalent USD: million USD: million USD: million 6% 1H24 1H25 1H24 1H25 1,036.0 978.3 （11.5） (38.0) (33.5) (70.2) 66% 46% narrowed narrowed 24-Dec 25-Jun Note: Balance includes cash and cash equivalents, pledged depos
Slide 21: Contents
Contents Company Highlights Business Review Financial Review Appendix
Slide 22: Product Pipeline
Product Pipeline Piezoelectric Piezoelectric Cardio- Coronary Stent Graft Firehawk® Coronary Sinus Balloon Coronary Laser Ablation Guide Extension Guidewire Guidewire vascular System FDA Counterpulsation System System Catheter Equipment accessories Shoulder New Primary Procotyl P Dual Mobility Wrist
Slide 23: Consolidated Income Statement
Consolidated Income Statement USD'000 2025 1H 2024 1H Var. Revenue 547,532 558,702 -2.0% Cost of sales (238,956) (228,122) 4.7% Gross profit 308,576 330,580 -6.7% Research and development costs (72,078) (115,033) -37.3% Distribution costs (148,551) (156,150) -4.9% Administrative expenses (82,785) (8
Slide 24: Consolidated Balance Sheet
Consolidated Balance Sheet USD'000 30 June 2025 31 Dec 2024 Var. Non-current assets Investment properties 4,176 4,214 -1% Property, plant and equipment 916,420 934,159 -2% Intangible assets 229,100 234,317 -2% Goodwill 201,100 188,514 7% Equity-accounted investees 402,029 382,861 5% Financial assets
Slide 25: Consolidated Balance Sheet (cont'd)
Consolidated Balance Sheet (cont’d) USD'000 30 June 2025 31 Dec 2024 Var. Non-current liablities Interest-bearing borrowings 722,294 757,711 -5% Lease liabilities 38,282 47,932 -20% Deferred income 53,735 51,491 4% Contract liabilities 31,227 26,948 16% Convertible bonds 380,073 374,224 2% Other pay
Slide 26: MicroPort
MicroPort 00:00:05 115 30 \F Hands on details: | ++ ooeose Eyes for greatness Hands on details ++ ooo +e oee